Pharmacist Services - FCI Sheridan

The contract pertains to the provision of pharmacist services at the Federal Correctional Institution (FCI) Sheridan in Oregon, with the sole purpose of ensuring uninterrupted healthcare delivery to the inmate population during an interim period. The acquisition is justified under FAR Deviation 6.104-1(a), citing the need for continuity of care due to the incumbent contractor, Ghost Rx, being the only entity with pre-completed credentialing, security clearances, and established operational infrastructure capable of maintaining seamless service without interruption. The proposed period of performance is for one month, from June 1, 2026, through June 30, 2026, with an estimated cost of $9,188.48, funded under agency code 15B600, and executed via monthly firm-fixed-unit-price purchase orders. Full and open competition is waived because no other contractor can meet the urgent requirement to prevent any lapse in medical services, and the Government intends to follow this interim arrangement with a Blanket Purchase Agreement featuring a base period and four option years, all under firm fixed unit pricing. The contracting office, part of the Department of Justice’s Federal Bureau of Prisons, Western Regional Office in Stockton, California, is led by Contracting Officer Gene Rojas, who is the sole point of contact. No standard FAR contract clauses are included, as this is a justification for non-competitive acquisition rather than a full solicitation. Security clearance submissions for institution-based providers are required within 30 days of award, with an additional 30 days anticipated for adjudication. The contractor must maintain existing personnel and comply with Bureau of Prisons healthcare protocols without deviation. No evaluations, inspection criteria, packaging requirements, payment instructions, or formal representations from the offeror are documented beyond the sole-source justification, which relies entirely on the unique and irreplaceable capabilities of the incumbent. The follow-on Blanket Purchase Agreement will be competed but is not yet defined in scope, pricing, or structure beyond its anticipated use of firm fixed unit pricing.